Proactiveinvestors recommends
Additional Information
Market: OTCBB
Sector: Pharmaceuticals
EPIC: ACCP
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Access Pharmaceuticals
accesspharma.com/index.shtml

Access Pharmaceuticals (ACCP:  OTCBB) is an emerging specialty pharma company developing and commercializing propriety products for the treatment and supportive care of cancer patients.  MuGard, its FDA approved treatment for oral mucositis, is commercially launched in Europe, and will launch in the US and Asian in 1Q 2010.  ProLindac, which is in pivotal clinical trials, is a new and improved version of Sanofi-Aventis’ Eloxatin, a DACH Platinum chemotherapeutic.  Thiarabine is in human trials for the treatment of leukemias and lymphomas.  Lastly, ACCP has collaborations in the areas of oral insulin and oral human growth hormone, using it’s proprietary Cobalamin based oral drug delivery platform.

Full Access Pharmaceuticals profile here
Pdf

Access Pharmaceuticals To Raise $6.0 Million In Financing

10th Dec 2010, 7:53 pm
Access Pharmaceuticals To Raise $6.0 Million In Financing

Access Pharmaceuticals (OTCBB: ACCP), an emerging biopharmaceutical company that develops products for the supportive care of cancer patients, announced today it will sell about $6 million worth of stock to accredited investors via a registered direct offering.

The offering consists of 2.3 million shares at $2.55 per share.

At closing, Access will also issue to investors warrants to buy a total of 0.7 million shares of common stock at a price of $3.06 per share.  The warrants are exercisable immediately for a term of 5 years from the closing date.

"In addition to providing Access capital to support the commercial launch of MuGard, this financing should prove to be a positive for Access investors, as it also helps shore up our balance sheet for partnering discussions in our various programs," said CEO Jeffrey B. Davis.

The company's MuGard product is a treatment for the inflammation of the mouth's mucosa caused by radiation and chemotherapy in cancer patients.

Hudson Securities, a subsidiary of Hudson Holding Corp.(OTCBB: HDHL), acted as Access' placement agent for the offering.

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.